168 related articles for article (PubMed ID: 23985000)
1. Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?
Machado MV; Cortez-Pinto H
Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):513-5. PubMed ID: 23985000
[TBL] [Abstract][Full Text] [Related]
2. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
[TBL] [Abstract][Full Text] [Related]
3. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
[TBL] [Abstract][Full Text] [Related]
4. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.
Polyzos SA; Perakakis N; Mantzoros CS
Metabolism; 2019 Jul; 96():66-82. PubMed ID: 31071311
[TBL] [Abstract][Full Text] [Related]
5. Leptin decreases de novo lipogenesis in patients with lipodystrophy.
Baykal AP; Parks EJ; Shamburek R; Syed-Abdul MM; Chacko S; Cochran E; Startzell M; Gharib AM; Ouwerkerk R; Abd-Elmoniem KZ; Walter PJ; Walter M; Muniyappa R; Chung ST; Brown RJ
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573497
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function.
Bruder-Nascimento T; Kress TC; Belin de Chantemele EJ
F1000Res; 2019; 8():. PubMed ID: 31656583
[TBL] [Abstract][Full Text] [Related]
7. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.
Javor ED; Cochran EK; Musso C; Young JR; Depaoli AM; Gorden P
Diabetes; 2005 Jul; 54(7):1994-2002. PubMed ID: 15983199
[TBL] [Abstract][Full Text] [Related]
10. 20 years of leptin: leptin in common obesity and associated disorders of metabolism.
DePaoli AM
J Endocrinol; 2014 Oct; 223(1):T71-81. PubMed ID: 24973357
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
[TBL] [Abstract][Full Text] [Related]
12. Post-liver transplant leptin results in resolution of severe recurrence of lipodystrophy-associated nonalcoholic steatohepatitis.
Casey SP; Lokan J; Testro A; Farquharson S; Connelly A; Proietto J; Angus PW
Am J Transplant; 2013 Nov; 13(11):3031-4. PubMed ID: 24007548
[TBL] [Abstract][Full Text] [Related]
13. Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.
Bolze F; Bast A; Mocek S; Morath V; Yuan D; Rink N; Schlapschy M; Zimmermann A; Heikenwalder M; Skerra A; Klingenspor M
Diabetologia; 2016 Sep; 59(9):2005-12. PubMed ID: 27272237
[TBL] [Abstract][Full Text] [Related]
14. The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.
Gorden P; Park JY
Arch Physiol Biochem; 2006 Apr; 112(2):114-8. PubMed ID: 16931453
[TBL] [Abstract][Full Text] [Related]
15. Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings.
Akinci B; Subauste A; Ajluni N; Esfandiari NH; Meral R; Neidert AH; Eraslan A; Hench R; Rus D; McKenna B; Hussain HK; Chenevert TL; Tayeh MK; Rupani AR; Innis JW; Mantzoros CS; Conjeevaram HS; Burant CL; Oral EA
Med; 2021 Jul; 2(7):814-835. PubMed ID: 35291351
[TBL] [Abstract][Full Text] [Related]
16. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
[TBL] [Abstract][Full Text] [Related]
17. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease.
Machado MV; Coutinho J; Carepa F; Costa A; Proença H; Cortez-Pinto H
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1166-72. PubMed ID: 22735605
[TBL] [Abstract][Full Text] [Related]
18. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
Akinci G; Akinci B
Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance, acanthosis nigricans, and hypertriglyceridemia.
Eberting CL; Javor E; Gorden P; Turner ML; Cowen EW
J Am Acad Dermatol; 2005 Feb; 52(2):341-4. PubMed ID: 15692481
[No Abstract] [Full Text] [Related]
20. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.
Shimomura I; Hammer RE; Ikemoto S; Brown MS; Goldstein JL
Nature; 1999 Sep; 401(6748):73-6. PubMed ID: 10485707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
